top of page
  • Incubate Coalition Japan

INCUBATE X JAPAN 2023 – 日経フォーラム:ライフサイエンスエコシステムにおけるイノベーションを育む

2023年4月12日 (日本・東京)

4月12日、Incubateは日本経済新聞社と共同で、「Incubating Innovation in the Life Science Ecosystem (ライフサイエンスエコシステムにおけるイノベーションを育む)」と題したフォーラムを東京で開催しました。このイベントには、ドイツ、米国、イスラエルから5人の有力ベンチャーキャピタリスト (VC) が参加し、世界各地から120人の参加者が集まりました。このフォーラムは、日本がいかにしてアーリーステージのライフサイエンスエコシステムを強化し、イノベーションの世界的強国としての役割を高めることができるかを議論する場となりました。プログラムは、経済産業省 (METI) の西川和見氏を招いた民間関係者の昼食会から始まり、2時間の公開シンポジウム、そして夜のレセプションが行われました。Incubateと参加VCは4月13日、プライベートミーティングを開催しました。


聴衆は117人で、そのうち76人が地元東京近郊からの参加で、46人が外国からの参加でした。出席者の大半は食品、製薬、化粧品分野に従事しており、参加者の17%が管理職または指導的立場にある人でした。日本経済新聞社がイベント参加者に実施したフォローアップ調査では、回答者の95%がイベントに満足したと答え、62%が非常に満足したと回答していました。国会議員をはじめ、厚生労働省、経済産業省の職員や政府関係者も出席しました。



注目の講演者:


シンポジウムの講演者は、プログラム順に以下の通りです。


「日本のライフサイエンスの現状」

このセクションでは、ライフサイエンスのエコシステムを機能的かつ繁栄させるために必要なさまざまな要素を描くことを目的としました。講演者は、投資、研究、民間企業、創業者、政府、スタートアップなど、それぞれの立場から発言しました。

  • 山本 剛氏 (厚生労働省 医政局 医薬産業振興・医療情報企画課 ベンチャー等支援戦略室 室長)

  • 小柳 智義氏 (京都大学医学部附属病院先端医療研究開発機構 (iACT) ビジネスディベロップメント室長・特定教授)

  • 長久 厚氏 (DNAパートナーズLLC社長)

  • 藤本 利夫氏 (アイパークインスティチュート株式会社 代表取締役社長)芦田 広樹氏 (エイトローズベンチャーズジャパン バイスプレジデント)

  • 永山 治氏 (中外製薬名誉会長)


「お金以上のもの: 投資家の視点」

日本経済新聞社の司会で行われたこのパネルディスカッションでは、VCがグローバル市場において過去に直面した課題、日本への提言、バイオ技術スタートアップ支援における具体的な役割、大学での研究を民間企業向けにデータ化することなどが話し合われました。

  • Christine Brennan氏 ( Vertex Ventures HC マネージングディレクター)、Johannes Fruehauf氏 (LabCentral共同設立者、Mission BioCapital ゼネラルパートナー)、Michal Silverberg氏 (Novartis Venture Fund マネージングディレクター)

  • ·Sascha Berger (TVM Capital パートナー)


「今日と明日のチャンス」

Dr. Gaurav Gupta (J.P. Morgan Life Sciences Private Capital マネージングパートナー)、Steve Ubl氏 (Pharmaceutical Research and Manufacturers of America プレジデント兼CEO) を交え、John Stanford (Incubate エグゼクティブディレクター) がモデレーターを務めた徹底対談。


Christine Brennan

Christine has over 15 years in the life-science industry including business development, corporate strategy and venture investing. She is currently Managing Director at Vertex Ventures HC (VVHC) where she is board director for Boundless Bio and Redona Therapeutics as well as board observer for Epirium Bio and Matchpoint Therapeutics. Prior to VVHC, she was a Partner at MRL Ventures Fund from 2017-2021 where she was on the boards of Alector, Inc. [NASDAQ:ALEC], Entrada Therapeutics [NASDAQ:TRDA], Tallac Therapeutics and Therini Bio. She was also an observer on the boards of Adagio [NASDAQ:ADGI], LifeMine Therapeutics, PAQ Therapeutics and Translate Bio [NASDAQ:TBIO]. Prior to MRL Ventures Fund, she was Principal at the Novartis Venture Fund from 2013-2017 where she was on the board of Altimmune [NASDAQ:ALT] and an observer on the boards of a number of companies including ROX Medical, lnnocrin Pharmaceuticals, Viamet Pharmaceuticals and Quartet Medicine. Prior to Novartis Venture Fund, she was Chief Business Officer at Vitae Pharmaceuticals from 2010-2013. She also held positions in business development and marketing at small and mid-size biopharmaceutical companies. Christine received her Ph.D. in neuroscience from Dartmouth Medical School and was post-doctoral fellow in developmental neurobiology at the National Institutes of Health.

Johannes Fruehauf

With his background as a physician working in diverse health systems, coupled with 20+ years as a serial biotech entrepreneur, Dr. Fruehauf has dedicated much of his professional endeavors to supporting life science entrepreneurs and start-up companies. Dr. Fruehauf is currently General Partner and co-founder of Mission BioCapital (MBC). In his role at MBC, Johannes sources, diligences, and leads new life-science investment transactions and represents the fund on the board of a number of MBC portfolio companies.

He is also the Founder and President of LabCentral and BioLabs, the largest provider of laboratory co-working space for startups nationwide, currently serving over 385+ startups in 15 cities. Over the past three years, the companies started within this network secured over 25% of all Seed and Series A venture capital invested in life sciences in the US. LabCentral and BioLabs were also the recipient of the prestigious Prix Galien Award in 2022 for the best biotech startup launchpads in the “Incubators, Accelerators and Equity” category.

Johannes studied medicine in Germany and France, while also conducting field work in Africa (Zimbabwe and Guinea). Thereafter, he practiced medicine (internal medicine and OB/Gyn) for several years in Germany before coming to Boston for a post-doc at Beth Israel Deaconess Medical Center/Harvard Medical School. Johannes graduated from University of Frankfurt and received his doctorate from the University of Heidelberg. He is also the author of over 30 peer reviewed publications and is named inventor on 9 issued patents on drug delivery and RNAi-based therapeutics.


Michal Silverberg

Michal Silverberg is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA. Prior to joining NVF, she was a Senior Partner at Takeda Ventures and, before that, worked at Novo Nordisk in roles of increasing responsibility including as Senior Director Business Development and New Product Commercialization, serving as a member of the BioPharm leadership team. Since 1998, Michal has held positions in various sectors of the life science industry including in the Office of the Chief Scientist of Israel (The Incubator program), venture capital (Ofer Brothers Hi Tech) and global pharmaceutical and biotech companies, including various positions at MGVS, an Israeli biotech company and at OSI Pharmaceuticals in a business development role. She received her B.A. in Economics and Business Management from Haifa University, her M.B.A from Tel-Aviv University in Israel and her Master’s degree in Biotechnology from Columbia University in New York.

Sascha Berger

Dr. Sascha Berger is a Partner at TVM Capital, based in Munich, Germany. TVM Capital is one of the transatlantic Life Science Venture Capital pioneers, investing with teams in Europe and North America. Sascha joined TVM Capital in 2016, helped to raise the current $480M fund, and works closely with entrepreneurs and founders to advance promising pharmaceutical assets, medtech, diagnostic, and digital health technologies to the next value inflection points. Sascha is a passionate VC, a Boston Consulting Group alumnus, and has an academic background in chemistry and finance.


John Stanford

John Stanford is the Executive Director of Incubate, a coalition of venture capital organizations who represent the patient, investment, and corporate communities. In this role he is responsible for communicating priorities that encourage life science innovators to grow in the US, and strengthening intellectual property provisions in the US and globally. John has been recognized in the Congressional Record and in state legislatures for his advocacy and communication efforts. He comments regularly on health and policy issues, most recently in the Wall Street Journal, STAT, CNBC, the Washington Post and the International Business Times. John is also the host of the new Making Medicine podcast, which features leading investors, biotech CEOs and policymakers to discuss the early-stage ecosystem. He most recently presented at the JP Morgan Healthcare Conference 2023, speaking on multiple panels about the state of drug pricing policy and the IRA. John is a Denver, CO native, and graduated from the College of William & Mary with a B.A. in Government and has an M. Ed. In Secondary Education from Arizona State University.

Stephen J. Ubl

Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. Mr. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery, and access to life-saving medicines. “If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl,” the New York Times wrote in February 2016. “He is more conversant with the intricacies of health policy, and more adept at the politics.” He is routinely recognized as one of Washington’s most effective advocates, and, in 2019, was named one of Business Insider’s “DC Healthcare Power Players.” He is consistently named to Modern Healthcare’s “100 Most Influential People in Healthcare” list and is identified as a top health influencer by Medical Marketing & Media and PR Week magazines.


Keiichi Murayama

Keiichi Murayama formerly served as the U.S. Silicon Valley bureau chief of Nikkei Inc., and was a senior staff writer and an editorial writer of Nikkei. After earning his undergraduate degree at Tohoku University in 1992, he joined the Business News Department of Nikkei in Tokyo as a staff writer. He covered technology, medical, automotive, and financial news. After he joined the Program on US-Japan Relations at Harvard University, he went on to oversee the U.S. Silicon Valley Bureau for a few years. He has authored numerous publications including “Rise and Fall of the IT Empire – Steve Jobs Revolution” and “STARTUP – The Reality of Entrepreneurs”.

Atsushi Nagahisa

Atsushi Nagahisa, PhD is President and CEO of DNA Partners, LLC. He has over 35 years of experience in drug discovery, development and management. Nagahisa was previously Vice President of Pfizer Global Research and Development, Director of Pfizer Nagoya Laboratories, and Senior Vice President for R&D of Pfizer Japan. He raised $111 million to found RaQualia, Inc. in 2008, Pfizer’s first organic spinoff. He was President and CEO of RaQualia from its formation to 2012 and led its successful IPO in 2011 on the JASDAQ. Nagahisa headed laboratories in Pfizer that discovered Cerenia and Galliprant. He has authored or co-authored more than 50 publications in scientific journals. In 2011, Pharmaceutical Executive named him one of the 30 most impactful individuals in the biopharmaceutical sector over the 30-year history of the magazine.





閲覧数:8回0件のコメント

最新記事

すべて表示

2024年度国民健康保険薬価制度改革骨子案と2024年度費用対効果評価制度改革骨子案に関するIncubateの声明

中央社会保険医療協議会(以下「中医協」)は今週、2024年度国民健康保険薬価制度改革骨子案(以下「薬価制度改革骨子案」)と2024年度費用対効果評価制度改革骨子案(以下「費用対効果評価制度改革」)を決定しました。 日本のバイオ医薬品産業への投資拡大を目指すアーリーステージのライフサイエンスベンチャーキャピタルの立場から、Incubateはこれらの改革を支持します。 Incubateは、日本市場とバ

Comments


bottom of page